Fragmentation-Induced Coverage Biases in Cell-Free DNA Sequencing Affect the Clinical Sensitivity of Liquid Biopsies.
Cancer DNA in blood fragments unevenly across the genome due to chemistry, creating blind spots in liquid biopsy—insights for improving test design.
This study demonstrates that cfDNA's epigenetically driven fragmentation patterns produce systematic coverage biases in sequencing that are distinct from solid-tissue DNA, potentially leading to under-representation of clinically relevant genomic regions and reduced liquid biopsy sensitivity. The findings have direct implications for improving cfDNA assay design and computational pipelines to mitigate fragmentation-induced blind spots in ctDNA cancer detection.
What the study was
- Study design
- Analytical and computational methods study
- Population
- Cell-free DNA from blood samples analyzed for fragmentation patterns and sequencing coverage biases
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Communications biology
Why it surfaced
Methodological study with direct implications for improving clinical liquid biopsy sensitivity; fragmentation biases represent a systematic quality issue affecting multiple commercial cfDNA assay platforms.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.